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Abstract 
This study uses a stepwise regression model to measure the efficacy of vaccination in reducing 
COVID-19 case rates through 8/10/21.  In order to hold other covariants constant, variables like 
density, poverty, and governmental stringency were also included in the regression tests.  The 
statistical results rigorously show that higher vaccination rates led to significantly lower COVID-
19 case rates at the state level.  A simulation is presented that estimates the cumulative COVID-
19 case rate had vaccinations not been available.  With respect to the other variables tested, 
density was significant in positively affecting case rates in 2021 after not being significant in the 
last half of 2020.  Poverty rates were significant during all periods tested in the study.  
Surprisingly, governmental stringency as measured by the Oxford Stringency Index was not 
found significant in reducing COVID-19 case rates in 2021.  Finally, no significant evidence of 
herd immunity was found in 2021. 
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1   Introduction 
A number of academic studies have studied the impact of vaccinations on COVID-19 
case rates.  These studies, however, do not investigate statewide differences and how those 
differences can be used to estimate the efficacy of COVID-19 vaccination rates. 
In Moghadas (Moghadas et al., 2020), the authors conclude that COVID-19 vaccines will 
be 95 percent effective in preventing disease.  Their estimates are a priori in nature and do not 
include any ex-post tests on the efficacy vaccines.  A study that is ex-post and does review 
statewide reports concludes that fully vaccinated individuals are “unlikely” to get COVID-19 and 
that vaccines are “highly effective” (Kates et al., 2021).  Its major limitation is that the statewide 
data used are not consistent and are reported by different resources.  As the authors conclude: 
 
Moving forward, particularly as the more transmissible Delta variant is 
now the dominant strain of COVID-19 circulating in the U.S., more robust state-
level data will help to monitor ongoing vaccine effectiveness and inform 
discussions about booster vaccinations (Kates et al., 2021, page 4). 
 
Gostin (Gostin et al., 2021) present an interesting study on how mandatory SARS-CoV-2 
vaccinations in K-12 schools, colleges, universities, and businesses may improve the public’s 
health.  The examination, however, does not present empirical findings.  Rather, it is a review 
and summary of possible effects.  Another study that examines COVID-19 infections at U.S. 
colleges and universities (Davis and Zacher, 2021, page 1) finds that “infection rates are higher 
at public institutions.”  But in spite of the fact that the study covers the 2020-21 academic year, 
there are no empirical findings relating to the efficacy of vaccinations. 
In a study involving 10,813 subjects in Guangdong, China, it was concluded that “full 
vaccination with inactivated vaccines is effective against pneumonia, severe and critical illness 
caused by the B.1.617.2 variant (Kang et al., 2021, page 2).  The authors use one-way analysis of 
variance (ANOVA) as well as multivariate logistic regressions to estimate the vaccine’s 
effectiveness.  These statistical tools, however, are only used to test the effectiveness of being 
vaccinated or not with a single sample.  The study does not measure the specific effects of 
increasing vaccination rates. 
A study that comes closer to a statewide analysis is one that examines diverging patterns 
of COVID-19 cases in 7 countries with high vaccination rates (Bukhari et al., 2021).  The study 
concludes somewhat ambiguously that “the number of cases and deaths have declined 
significantly (with vaccinations ≥  50%), whereas in others they have increased compared to pre-
vaccination levels” (Bukhari et al., 2021 page 1).  More problematical is the fact that the period 
of testing in this paper ends on May 30, 2021, and it does not account for covariates that could 
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In Singer (Singer et al., 2021), the authors test the effectiveness of a vaccine against the 
SARS-CoV-2 variant identified through contract tracing in Israel.  Although the examination 
concludes that two doses of the BNT162b2 vaccine confer protection against Beta COVID-19 
infection, the testing period ends on March 25, 2021.  As in the Kang study in Guangdong, China 
(Kang et al., 2021), the Singer study does not test the case rates for samples with continuous 
vaccination rates. 
The lack of research on the efficacy of vaccinations at the statewide level is regrettable.  
With so much attention being given to the success or lack thereof in strategies designed to 
increase vaccination rates in a state, more academic research at the state level can measure how 
differing vaccination rates affect COVID-19 case rates. 
In the study to follow, the efficacy of cumulative vaccination rates from 1/1/21 to 8/10/21 
at the state level will be examined. A stepwise regression model similar to that of Doti (Journal 
of Bioeconomics, 2021; COVID Economics, 2021) will be used to measure the vaccine’s efficacy 
while holding other covariates like density, poverty, and governmental stringency constant.  Such 
regression tests will have the added benefit of measuring the explanatory impact of these 
covariates. 
This study will also estimate the impact of each state’s mean vaccination rate on its mean 
case rate and carry out a number of “what-if” scenarios.  The study also measured the potential 
impact of herd immunity.  It will conclude by extending the research beyond case rates to 
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2   Theoretical Model 
 The benefits of higher vaccination rates are depicted in Figure 1, where the downward 






 If a state or nation has a mean vaccination rate of V0, its corresponding rate of COVID-19 
cases is C0.  But if that state or nation increased its mean vaccination rate to V1, it is 
hypothesized that the COVID-19 case rate for that area will drop to C1.  
 In the study to follow, Section 3 will present an empirical model for measuring the impact 
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3   Empirical Model 
 In order to measure the impact of statewide differences in vaccination rates on COVID-
19 case rates, it will be necessary to hold constant other variables that influence COVID-19 cases 
as well as define more precisely the variables to be used in formulating the empirical tests. 
Cumulative confirmed COVID-19 cases per 100,000 in state population during the 1/1/21 
to 8/10/21 period serves as the dependent variable in the model.  A case is defined as a person 
who meets the clinical and epidemiological criteria for a SARS-CoV-2 infection. 
The structural form of the model is shown below in Equation (1).  
 
Ci,t = b0 + b1(x1,i) + b2(x2,i) + … + bn(xn,i)     (1) 
where Ci,t  is the cumulative COVID-19 case rate per 100,000 in state i at the end of some period 
t.  x1, …,  xn  = 1, …, n independent variables in state i.  b0, b1, …, bn = n parameters to be 
estimated. 
 
Note: Display of error terms are suppressed. 
 
Equation (1)  can also be estimated in exponential form using natural logs (ln). 
 
In order to control and test for the factors that explain the cumulative COVID-19 case 
rate by state during some time interval t, the following variables shown below in Equation (2) 
were selected. 
 
casei,t = bo + bv vaccinei + ∑ bd,t2d=1   densityi +  ∑ by,t2y=1   incomei +  
              bt stringencyi        (2) 
       
where casei is the cumulative COVID-19 case rate per 100,000 in state i during some period t.  
bo, bv, bd, by, bs are parameters to be estimated. 
 
Note: Displays of error terms are suppressed, and the definition and measured statistics for the 
dependent and independent variables are as shown in Table 2. 
 
 The vaccination rate, as defined in Table 2, represents the mean of the single dose or 
more daily rate from 1/1/21 to 8/10/21.  As shown in Table 1,  the statewide mean rates over that 
period range from a high of 53.6 percent in Vermont to a low of 29.6 in Mississippi.  Figure 2 
shows the weekly U.S. mean cumulative vaccination rate as compared to the outlier states 
Vermont and Mississippi from 1/1/21 to 8/10/21. 
 





















In Rank Order 
from 1/1/21 
to 8/10/21
1 Alabama 30.9 1 Vermont 53.6
2 Alaska 40.4 2 Massachusetts 52.2
3 Arizona 38.8 3 Connecticut 51.0
4 Arkansas 33.5 4 Hawaii 50.6
5 California 45.6 5 Maine 50.1
6 Colorado 43.5 6 New Hampshire 49.7
7 Connecticut 51.0 7 New Mexico 48.7
8 Delaware 43.7 8 Rhode Island 48.5
9 Florida 40.2 9 New Jersey 47.9
10 Georgia 32.8 10 Pennsylvania 46.5
11 Hawaii 50.6 11 Maryland 45.7
12 Idaho 31.7 12 California 45.6
13 Illinois 44.3 13 Washington 44.9
14 Indiana 34.6 14 New York 44.7
15 Iowa 40.5 15 Virginia 44.4
16 Kansas 38.9 16 Illinois 44.3
17 Kentucky 38.8 17 Delaware 43.7
18 Louisiana 31.1 18 Minnesota 43.7
19 Maine 50.1 19 Colorado 43.5
20 Maryland 45.7 20 Oregon 43.1
21 Massachusetts 52.2 21 Wisconsin 41.9
22 Michigan 39.4 22 South Dakota 41.4
23 Minnesota 43.7 23 Iowa 40.5
24 Mississippi 29.6 24 Alaska 40.4
25 Missouri 35.0 25 Florida 40.2
26 Montana 38.1 26 Nebraska 40.1
27 Nebraska 40.1 27 Michigan 39.4
28 Nevada 37.9 28 Kansas 38.9
29 New Hampshire 49.7 29 Kentucky 38.8
30 New Jersey 47.9 30 Arizona 38.8
31 New Mexico 48.7 31 Montana 38.1
32 New York 44.7 32 Nevada 37.9
33 North Carolina 36.9 33 Ohio 37.5
34 North Dakota 36.6 34 North Carolina 36.9
35 Ohio 37.5 35 Utah 36.8
36 Oklahoma 36.4 36 North Dakota 36.6
37 Oregon 43.1 37 Oklahoma 36.4
38 Pennsylvania 46.5 38 Texas 36.0
39 Rhode Island 48.5 39 West Virginia 35.3
40 South Carolina 34.5 40 Missouri 35.0
41 South Dakota 41.4 41 Indiana 34.6
42 Tennessee 32.6 42 South Carolina 34.5
43 Texas 36.0 43 Arkansas 33.5
44 Utah 36.8 44 Georgia 32.8
45 Vermont 53.6 45 Tennessee 32.6
46 Virginia 44.4 46 Wyoming 32.3
47 Washington 44.9 47 Idaho 31.7
48 West Virginia 35.3 48 Louisiana 31.1
49 Wisconsin 41.9 49 Alabama 30.9
50 Wyoming 32.3 50 Mississippi 29.6
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 As shown in Table 2, there are two density variables where a super density variable was 
added to the regression test because density, as generally measured, does not adequately measure 
its impact on COVID-19 cases on a state-level basis (Doti, Journal of Bioeconomics, 2021).   A 
state’s density (density) is defined as the population of that state divided by its total geographic 
area in square miles or as shown in Table 2: population density per square mile.  Although that 
measure is relevant for most states, it is not necessarily so for those states where a highly 
populated metropolitan area exhibits extremely high density.  For example, New York City’s 
density is the ratio of its population of 8.2 million (2010 Census) to its land area of 302.6 square 
miles.  The resulting density of New York city of 27,016, compares to New York state’s density 
of 169.  Using a state-level density of 169 for New York state would miss the impact of the 
extraordinarily high rate of density for the city. 
 In order to capture that impact on a state-level basis, all cities in the nation with a 
population of 300,000 or more that had a population density of at least 10,000 people per square 
mile were identified and measured as a ratio of each state’s total population. The resulting ratios, 
in turn, were multiplied by the density of the metropolitan areas that met the selection criteria 
presented above.  In the structural form of the model, this density variable (sdensity) is given by 
 
 sdensityi,t =   ∑ pk,i / Pi,t 
ni
k=1   * densityi,t     
 
where pk,i is population of the kth city in state i with a population > 300,000 and density  
> 10,000 per mile2.  ni is number of cities in state i with population > 300,000and density  
> 10,000 per mile2.  Pi,t is population of state i as of some period t.  densityi,t is density of state i 
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Two income variables, per capita personal income in thousands (py) and the poverty rate 
(poverty) are included to hold constant the impact of a state’s income on that state’s COVID-19 
case rate. 
 The efficacy of a state’s governmental regualtions that impose various mandates in order 
to control the spread of COVID-19 is measured by the Oxford daily governmental stringency 
index (stringency).  This index measures the stringency of statewide governmental mandates on a 
daily basis, using a scale from 1 to 100.  The ordinal measures that comprise the Oxford index 
for every state include in its measurement the following governmental responses to COVID-19: 
 
– School closings 
– Workplace closings 
– Cancellation of public events 
– Restrictions on gathering size 
– Closures of public transit 
– Stay at home requirements 
– Restrictions on internal movements 
– Restrictions on international travel 
– Public information campaign 
– Testing policy 
– Contact tracing 
 
The daily Oxford stringency index used in this study was derived by calculating an 
average stringency index from the daily rates for each state during the 1/1/21 to 8/10/21 period.  
The derivation is given by: 
 
 stringencyi,t = ∑ stringencyi,dnd=1  / nt 
 
where stringencyi,t is the mean stringency index in state i as of some period t, stringencyi,d is the  
stringency index in state i as of a particular day, d, and nt is the number of days during period t. 
 
 Table 3 presents the mean stringency index by state in alphabetical and rank order from 
highest to lowest over the 1/1/21 to 8/10/21 period. 
 The functional form of the equation that incorporates the impact each state’s vaccination 
rate, density, income and stringency is shown below in Equation (3). 
 
casei = bo + b1 vaccinei + b2 densityi +  b3 sdensityi + b4 pyi + b5 povertyi + 
            b6 stringencyi   (3) 
 
where the variables for state i are as defined in Table 2 and b0 ……b6  are parameters to be 
estimated. 
 
Note: Error terms are suppressed. 
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The hypothesized signs of association in Equation (3) are shown in Equation (4): 
 
-          +             +         -            +                - 
casei = f  (vaccinei ; densityi ; sdensityi ; pyi ;  povertyi ; stringencyi)    (4) 
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Table 3





In Rank Order 
from 1/1/21     
to 8/10/21
1 Alabama 20.8 1 Hawaii 64.4
2 Alaska 42.4 2 Rhode Island 53.0
3 Arizona 27.4 3 California 49.8
4 Arkansas 31.9 4 Washington 47.9
5 California 49.8 5 Massachusetts 47.6
6 Colorado 33.9 6 New York 47.1
7 Connecticut 43.7 7 Oregon 46.7
8 Delaware 37.2 8 New Mexico 44.3
9 Florida 22.5 9 Vermont 43.9
10 Georgia 30.5 10 Connecticut 43.7
11 Hawaii 64.4 11 Louisiana 43.0
12 Idaho 28.5 12 Minnesota 42.8
13 Illinois 36.4 13 Alaska 42.4
14 Indiana 31.3 14 North Carolina 40.8
15 Iowa 18.5 15 Maryland 37.3
16 Kansas 31.0 16 New Hampshire 37.2
17 Kentucky 33.7 17 Delaware 37.2
18 Louisiana 43.0 18 Texas 36.9
19 Maine 36.1 19 Ohio 36.9
20 Maryland 37.3 20 Michigan 36.7
21 Massachusetts 47.6 21 Illinois 36.4
22 Michigan 36.7 22 Oklahoma 36.2
23 Minnesota 42.8 23 Maine 36.1
24 Mississippi 24.5 24 New Jersey 35.8
25 Missouri 31.4 25 Wisconsin 35.4
26 Montana 31.4 26 Wyoming 35.3
27 Nebraska 21.6 27 Virginia 35.1
28 Nevada 30.8 28 Colorado 33.9
29 New Hampshire 37.2 29 Kentucky 33.7
30 New Jersey 35.8 30 West Virginia 33.1
31 New Mexico 44.3 31 Arkansas 31.9
32 New York 47.1 32 Montana 31.4
33 North Carolina 40.8 33 Missouri 31.4
34 North Dakota 24.5 34 Indiana 31.3
35 Ohio 36.9 35 Kansas 31.0
36 Oklahoma 36.2 36 Nevada 30.8
37 Oregon 46.7 37 Georgia 30.5
38 Pennsylvania 29.4 38 Tennessee 29.9
39 Rhode Island 53.0 39 Pennsylvania 29.4
40 South Carolina 27.0 40 Idaho 28.5
41 South Dakota 9.3 41 Arizona 27.4
42 Tennessee 29.9 42 South Carolina 27.0
43 Texas 36.9 43 Mississippi 24.5
44 Utah 20.2 44 North Dakota 24.5
45 Vermont 43.9 45 Florida 22.5
46 Virginia 35.1 46 Nebraska 21.6
47 Washington 47.9 47 Alabama 20.8
48 West Virginia 33.1 48 Utah 20.2
49 Wisconsin 35.4 49 Iowa 18.5
50 Wyoming 35.3 50 South Dakota 9.3
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4   Impact of Vaccinations and Other Variables on COVID-19 Case Rates 
A stepwise model similar to that used by Doti (Doti, Journal of Bioeconomics, 2021 and 
Doti, COVID Economics, 2021) added the explanatory variables in groupings from I to IV, as 
shown in Table 4.  The regression results are presented in Regressions 1 to 5, Table 4. Note that 
explanatory variables were removed if not significant at the p < 0.10 level (one-tailed), and the 









Table 4.   Regression results,  dependent variable definition: mean cumulative case rate (COVID-19 cases per 
100,000 people by state) from 1/1/21 to 8/31/21, dependent variable name: cases
Regression 1 Regression 2 Regression 3 Regression 4 Regression 5
R-squared 0.06 0.47 0.54 0.53 0.53
Constant 6350.30 8256.13 7424.01 6201.75 6216.81
(6.15) *** (9.57) *** (4.80) *** (5.16) *** (5.22) ***
I.  Vaccination variable
vaccine -47.40 -109.36 -73.19 -80.81 -85.94
(-1.89) ** (-4.94) *** (-2.88) *** (-3.07) *** (-3.69) ***
II.  Density variables:
density 2.78 2.98 2.69 2.67
(5.32) *** (5.34) *** (5.31) *** (5.34) ***
sdensity 0.14 0.16 0.13 0.12
(1.85) ** (2.01) ** (1.69) ** (1.67) **
III.  Income variables
py -27.59
(-1.21)
poverty 5871.10 8149.38 7996.8
(1.55) * (2.38) ** (2.37) **
IV.  Policy Intervention
stringency -6.31
(-0.44)
Notes:  t statistics in parentheses. *p‹0.10,   **p‹0.05,   ***p‹0.01 (one-tailed test)
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4.1 Vaccination Variable, vaccine 
 
The estimated coefficient of -85.94 for the vaccination coefficient suggests that, on 
average, a state’s COVID-19 case rate decreases by 85.94 cases per 100,000 in a state’s 
population for every increase of 1 percent in a state’s average vaccine rate.  The measured t 
statistic of -3.69 for vaccine in Regression 5, Table 4, is highly significant at p < 0.01 level 
(one-tailed). 
The empirical findings of Regression 5 can also be used to estimate the “what-if” impact 
of a higher vaccination rate.  Following the theoretical model depicted in Figure 1, Figure 3 
shows the estimated change in the COVID-19 case rate that would result if the mean 
cumulative vaccination rate were 50.0 percent instead of the actual 40.1 over the 1/1/21 to 
8/10/21 period.  As shown in Figure 3, the estimated coefficient of -85.94 in Regression 5, 
Table 4 suggests that the COVID-19 case rate per 100,000 in U.S. population would decline 
by 851 or ([50.0 – 40.1] * -85.94).  That, in turn, suggests that the cumulative case rate in the 
U.S. on 8/10/21 would have been 3,572 or (4,423 – 851) instead of the actual rate of 4,423. 
Since the case rate is measured per 100,000 in population, the projected decline in the 
case rate from 4,423 to 3,572 is equivalent to a cumulative total number of COVID-19 cases 
on 8/10/21 of 11.8 million at an assumed 50.0 vaccination rate.  That compares to 14.6 
million cases at the actual vaccination rate of 40.1 for an estimated decline at the 50 percent 
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The empirical results of Regression 5 can also be used to estimate the “what-if” impact of 
having no COVID-19 vaccines available and, therefore, a zero vaccination rate.  As shown in 
Figure 4, estimated  COVID-19 vaccine case rates per 100,000 in U.S. population would 
increase by 3,446 or ([0 – 40.1] * -85.94).  As a result, the cumulative case rate in the U.S. 
from 1/1/20 to 8/10/21 would have been 7,869 or (4,423 + 3,446) per 100,000 had no vaccine 
been available.  That compares to the actual rate of 4,423 per 100,000 at an average 
vaccination rate of 40.1. 
Converting from the relative rate of 4,423 cases per 100,000 to 7,869 cases per 100,000 is 
equivalent to a total number of COVID-19 cases on 8/10/21 of 26.0 million at an assumed 
vaccination rate of zero and a U.S. population of 330 million.  That compares to the 14.6 
million cases at the actual average vaccination rate of 40.1 for an estimated increase at a zero 




The above estimate of an increase in the case rate of 3,446 per 100,000 in the U.S. and an 
increase of 11.4 million total cases is based on the mean vaccination rate of 40.1 from 1/1/21 
to 8/10/21.  It is also possible to use the estimated coefficient of -85.94 for the vaccination 
variable in Regression 5 to show the difference in cases on a daily basis.  During the 1/1/21 
to 8/10/21 period, the mean single dose or more vaccination rate in the U.S. increased from 
zero on 1/1/21 to 58.9 percent by 8/10/21. 
Figure 5 shows a comparison of the actual cumulative case rate as compared to a 
projected cumulative case rate assuming no vaccinations.  By 8/10/21, when the mean 
vaccination rate hit 58.9 percent, the difference between the cumulative case rate with 
FIGURE 4
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vaccinations of 4,423 per 100,000 compares to a projected 9,485 per 100,000 with no 
vaccinations.  That difference of 5,062 fewer cases per 100,000 in U.S. population is 
equivalent to a total reduction of 16.7 million COVID-19 confirmed cases with no 
vaccinations.  This decrease of 16.7 million cases is based on the vaccination rate of 58.9 
percent on 8/10/21 as compared to the 11.4 million decrease in the cumulative case rate at a 




The estimated coefficient of -85.94 for the vaccine variable in Regression 5, Table 4, can 
also be used to analyze the implications of the wide disparity in vaccination rates between 
Vermont and Mississippi, as depicted in Figure 2.  Recall that the mean cumulative 
vaccination rate for the highest vaccinated state, Vermont, was 53.6 percent versus a rate of 
29.6 for the lowest vaccinated state, Mississippi. 
When Vermont’s vaccinated rate of 53.6 is multiplied by the estimated coefficient of        
-85.94 for the vaccine variable, the resulting estimated decline in Vermont’s case rate is -
4,607 or (53.6 * -85.94).  Multiplying Mississippi’s case rate of 29.6 times the vaccine 
coefficient results in an estimated decline of 2,544 or (29.6 *-85.94).  The resulting 
difference in the estimated case rate for Vermont and Mississippi is 2,063 or (4,607 – 2,544).  
That difference almost fully accounts for the actual case rate of 5,061 for Mississippi and 
2,928 for Vermont since the difference of 2,133 or (5,061 less 2,928) is very close to the 
difference of 2,063 in the case rates.  This suggests that the wide disparity in Vermont and 
















1/1/21 2/1/21 3/1/21 4/1/21 5/1/21 6/1/21 7/1/21 8/1/21
FIGURE 5
Comparison of Actual and Es�mated Cumula�ve COVID-19 Case Rates
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Although Figures 3 and 4 are linear, a double logarithmic form of Regression 5, Table 4 




Although the R2 of 0.43 in the double logarithmic form of Regression 5 is lower than the 
R2 of 0.53 in the linear form of the equation (Regression 5, Table 4), the measured t statistic 
for the ln of vaccine (lnvaccine) is still significant at the p < 0.01 level.  In spite of the lower  
R2 value in the double logarithmic form of the equation, the measured coefficients have the 
desirable quality of representing constant elasticities across different values of the 
independent variables.  That means the -0.70 coefficient for lnvaccine variable represents the 
constant elasticity of the confirmed case rate with respect to the vaccination rate, which, in 
turn, suggests a one percent increase in the COVID-19 vaccination rate leads approximately 
to a 0.70 percent decrease in the COVID-19 case rate. 
 
Table 5
Regression 6, All Variables Measured in Natural Logs (ln) over the 1/1/21 to 8/10/21 period
Regression 6




I.  Vaccination variable
lnvaccine -0.70
(-2.77) ***





III.  Income variables
lnpoverty 0.25
(1.82) *
Notes:  t statistics in parentheses. *p‹0.10,   **p‹0.05,   ***p‹0.01 (one-tailed test)
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For comparison purposes, the average elasticity for vaccine in the linear form of the 
equation is shown in Equation 5. 
 
E  =  bv    
vaccine 
case
    = -85.94   40.66
4423.3
   = -0.79     (5) 
 
Although the average elasticity of -0.79 in the linear form of the equation compares 
closely to the constant elasticity of -0.70 in the double logarithmic form of the equation, the 
elasticity of -0.79 in the linear form of the equation will change as the vaccine variable 
deviates from its mean value of 40.66. 
 
 
4.2 Other Explanatory Variables 
 
Table 4 also presents the empirical results for the other explanatory variables used in the 
stepwise regression model.  The coefficients for density, sdensity, and poverty have the 
hypothesized signs of association as shown in Equation 4 and are all significant in 
Regression 5, at least at the p < 0.10 level.  Because they did not pass the p < 0.10 
significance test, the personal income variable, py, was dropped in Regression 4, and the 
stringency variable was dropped in Regression 5. 
 
 4.2.1 Density Variables 
 
The density and sdensity variables were both significant in Regression 5.  In fact, 
density was the most significant of all the explanatory variables tested.  There is 
empirical evidence, however, that suggests that the impact of the density variables on the 
case rate changed over time.  As shown in Table 6, density and sdensity were the most 
significant explanatory variables in the first half of 2020.  But during the second half of 
the year, the density variables were no longer significant.  These findings suggest that 
while COVID-19 hit dense states and highly dense urban areas particularly hard during 
the initial state of the pandemic (1/1/20 to 6/30/20), that impact fell away during the 
second half of the year (7/1/20 to 12/31/20).  This, in turn, suggests that it took about six 
months before the pandemic to move from densely populated urban areas to more rural 
areas.  Density, however, reared its head again in 2021 as its significance climbed.  This 
is especially the case of the density variable with its measured t of 5.34 as compared to 
the lower significance of the super density variable, sdensity, with a measured t of 1.67. 
 
4.2.2 Poverty Variable 
 
The poverty variable was significant during all three of the stages shown in Table 6 
but particularly so during the early 1/1/20 to 6/30/20 and 1/1/21 to 8/10/21 periods.  In 
the double logarithmic form of the equation reported in Table 5, the constant elasticity of 
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0.25 suggests that a one percent increase in a state’s poverty rate leads to a 0.25 percent 
increase in its COVID-19 case rate during the 1/1/21 to 8/10/21 period. 
  
4.2.3 Stringency Variable 
 
In analyzing the efficacy of governmental policy mandates, the empirical results 
shown in Table 6 suggest that the stringency variable was significant throughout 2020 
and particularly so during the 7/1/20 to 12/31/20 period.  In fact, stringency was the only 
explanatory variable during the second half of the year that had a p < 0.05 or higher level 
of significance.  But in 2021, it exhibited no significance in reducing statewide case rates.  
Note that its measure t statistic in Regression 4, Table 4 was only -0.44. 
A possible explanation for the sharp drop in the significance of the stringency in 
reducing COVID-19 case rates in 2021 is that states, on average, reduced their use of 
policy intervention.  This can be seen in Figure 6 that shows that the mean weekly 
stringency score steadily declined from 48.1 on 1/1/21 to 19.9 on 8/10/21.  Table 7 shows 
the statewide changes in mean stringency scores during three periods.  Note that the mean 
stringency score for all states declined from 47.0 during the 7/1/20 to 12/31/20 period to 















Density 1.26 -0.36 2.67
(-8.25) *** (-0.39) (5.34) ***
Super Density 0.11 -0.03 0.12
(4.73) *** (0.20) (1.67) **
Poverty 2184.5 8261.17 7996.8
(2.30) ** (1.36) * (2.37) ***
Stringency -6.47 -120.85 Not
(-1.94) ** (-5.48) *** Significant
Notes:  t statistics in parentheses. *p‹0.10,   **p‹0.05,   ***p‹0.01 (one-tailed test)
Comparison of Regression Results over Three Different Periods of Time, 
Dependent Variable: case
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Table 7








1 Alabama 30.5 31.6 20.8
2 Alaska 39.6 49.9 42.4
3 Arizona 31.1 39.8 27.4
4 Arkansas 30.9 42.2 31.9
5 California 43.5 59.0 49.8
6 Colorado 38.6 45.8 33.9
7 Connecticut 41.9 59.6 43.7
8 Delaware 46.6 53.4 37.2
9 Florida 40.9 40.3 22.5
10 Georgia 32.8 45.9 30.5
11 Hawaii 41.5 74.8 64.4
12 Idaho 35.2 42.8 28.5
13 Illinois 41.1 48.9 36.4
14 Indiana 35.5 39.1 31.3
15 Iowa 27.6 25.2 18.5
16 Kansas 35.1 41.7 31.0
17 Kentucky 45.6 51.7 33.7
18 Louisiana 33.7 49.1 43.0
19 Maine 46.5 63.2 36.1
20 Maryland 46.1 50.4 37.3
21 Massachusetts 38.8 58.4 47.6
22 Michigan 42.8 51.0 36.7
23 Minnesota 41.0 50.6 42.8
24 Mississippi 32.1 40.9 24.5
25 Missouri 34.1 38.8 31.4
26 Montana 38.3 42.5 31.4
27 Nebraska 35.1 36.0 21.6
28 Nevada 35.8 41.7 30.8
29 New Hampshire 40.6 39.9 37.2
30 New Jersey 38.3 49.1 35.8
31 New Mexico 46.7 74.8 44.3
32 New York 48.2 70.2 47.1
33 North Carolina 37.9 54.8 40.8
34 North Dakota 25.7 30.9 24.5
35 Ohio 43.3 54.4 36.9
36 Oklahoma 30.1 30.2 36.2
37 Oregon 35.7 52.2 46.7
38 Pennsylvania 37.7 48.5 29.4
39 Rhode Island 46.2 64.1 53.0
40 South Carolina 35.5 38.9 27.0
41 South Dakota 22.7 14.1 9.3
42 Tennessee 34.1 43.6 29.9
43 Texas 35.2 49.0 36.9
44 Utah 28.2 36.2 20.2
45 Vermont 41.1 58.9 43.9
46 Virginia 37.8 42.3 35.1
47 Washington 36.8 53.9 47.9
48 West Virginia 39.1 48.2 33.1
49 Wisconsin 33.8 40.0 35.4
50 Wyoming 35.6 42.2 35.3
Mean 37.4 47.0 35.1
Standard 
Deviation 5.8 11.6 9.7
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Figure 7 shows the steady decline in the mean weekly stringency score as compared 
to the mean weekly case rate in the U.S. during the 1/1/21 to 8/10/21 period. The sharp 
decline in the mean case rate from 65.0 at the beginning of 2021 to 3.7 by mid-June may 
explain the accompanying decline in the efficacy of the stringency variable during that 
period.  But even though the sharp Delta variant uptick led to an increase in the case rate 
from 3.7 on 6/16/21 to 28.7 by 8/10/21, the mean stringency score in the U.S. continued 




It might be argued that the functional form of the stringency variable changed and 
that change may account for it being insignificant in 2021.  To analyze that possibility, 
various values of stringency were tested in the model.  As an alternative to the stringency 
variable,stringency, stringencyl, was substituted.  The alternative stringency variable 
measured the absolute change in the mean stringency index value from the 7/1/20 to 
12/31/20 period to the mean value during the 1/1/21 to 8/10/21 period.  Another 
stringency variable, stringencyp, was substituted that measured the percentage change in 
the mean stringency index from the 7/1/20 to 12/31/20 period to the 1/1/21 to 8/10/21 
period. 
 As shown below, all three measured coefficients of stringency were insignificant. 
 
 stringency stringencyl stringencyp 
b�s  -6.31 -9.39 -1.51 
t-statistic (-0.43) (-0.42) (-0.14) 
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5   Impact on Statewide Case Rates 
The estimated coefficient for the vaccination rate, vaccine, can be used to estimate the 
impact of each state’s mean vaccination rate on its mean case rate.  Those estimates are presented 
in Table 7 and are based on Regression 5, Table 4.  The ΔC term in Equation 6 is represented by 
the ΔC term shown graphically in Figure 1 where C0 – C1 < 0. 
 
ΔC = [vaccinei] * b�v  * [Pi / 100,000]       (6) 
 
where ΔC = Reduction in the COVID-19 case rate from 1/1/21 to 8/10/21 as a  
                    result of an increase in the vaccination rate 
   vaccinei = The mean vaccination rate from 1/1/21 to 8/10/21 for state i 
             b�v = The estimated coefficient for vaccine (see Regression 5, Table 4)   
             Pi = The population of state i 
 
Note that Equation 6 above requires that the product include [Pi / 100,000] in order to convert 
case rates per 100,000 to the absolute reduction in the number of cases. 
  
 After aggregating the state-level results, Table 8 shows that COVID-19 vaccinations 
reduced the total number of infections in the U.S. by an estimated 10.4 million.  As a result, the 
actual total number of infections dropped from an imputed total of 26.1 million infections (10.4 
million + 15.7 million) with no vaccinations to 15.7 million infections, given each state’s actual 
mean vaccination rate.  These results are graphically depicted in Figure 8. 
 Note that the 10.4 million decline in total cases estimated by calculating the aggregate 
change of all 50 states is close to the 11.4 million cases calculated in Section 4.1 above that was 
estimated as an average for the U.S. as a whole (see Figure 4). 
 


































The Impact on COVID-19 Cases as a Result of Each State's Mean Vaccination Rate from 1/1/21 to 8/10/21
1 2 3 4
State
Reduction in the Number 
of COVID-19 Cases 
Resulting from State's 
Mean Vaccination Rate
Actual Number of        
COVID-19 Cases 
Projected Number of 
COVID-19 Cases with No 
Vaccinations                   
(sum of column 1 and 2)
Percentage Reduction in 
COVID-19 Cases as a Result 
of State's Mean 
Vaccination Rate                         
((column 1/ column 3)*100
1 Alabama 88,148                                250,161                              338,310                              26.1
2 Alaska 26,664                                31,681                                58,345                                45.7
3 Arizona 174,575                              420,571                              595,146                              29.3
4 Arkansas 83,098                                178,437                              261,535                              31.8
5 California 1,684,570                           1,711,724                           3,396,294                           49.6
6 Colorado 169,009                              248,164                              417,173                              40.5
7 Connecticut 133,506                              173,938                              307,443                              43.4
8 Delaware 31,530                                55,024                                86,554                                36.4
9 Florida 420,817                              1,445,700                           1,866,517                           22.5
10 Georgia 280,818                              553,815                              834,633                              33.6
11 Hawaii 77,895                                24,974                                102,869                              75.7
12 Idaho 44,807                                64,709                                109,516                              40.9
13 Illinois 393,400                              483,739                              877,138                              44.9
14 Indiana 181,722                              270,671                              452,393                              40.2
15 Iowa 50,324                                99,431                                149,754                              33.6
16 Kansas 77,513                                113,085                              190,598                              40.7
17 Kentucky 129,628                              237,429                              367,057                              35.3
18 Louisiana 171,568                              281,274                              452,842                              37.9
19 Maine 41,852                                46,769                                88,621                                47.2
20 Maryland 193,881                              194,936                              388,818                              49.9
21 Massachusetts 281,914                              355,226                              637,140                              44.2
22 Michigan 314,643                              493,045                              807,688                              39.0
23 Minnesota 208,171                              205,305                              413,476                              50.3
24 Mississippi 62,419                                150,149                              212,568                              29.4
25 Missouri 165,865                              267,039                              432,904                              38.3
26 Montana 29,162                                37,204                                66,367                                43.9
27 Nebraska 36,029                                64,191                                100,220                              35.9
28 Nevada 83,094                                140,657                              223,750                              37.1
29 New Hampshire 43,695                                56,277                                99,972                                43.7
30 New Jersey 273,146                              516,688                              789,833                              34.6
31 New Mexico 80,201                                71,636                                151,837                              52.8
32 New York 783,221                              1,184,958                           1,968,179                           39.8
33 North Carolina 371,683                              550,395                              922,078                              40.3
34 North Dakota 16,089                                19,791                                35,880                                44.8
35 Ohio 370,375                              445,512                              815,886                              45.4
36 Oklahoma 123,706                              210,146                              333,852                              37.1
37 Oregon 170,337                              118,508                              288,844                              59.0
38 Pennsylvania 322,712                              591,481                              914,193                              35.3
39 Rhode Island 48,141                                68,586                                116,727                              41.2
40 South Carolina 120,965                              338,338                              459,303                              26.3
41 South Dakota 7,168                                   26,433                                33,602                                21.3
42 Tennessee 177,034                              340,210                              517,244                              34.2
43 Texas 931,790                              1,489,471                           2,421,261                           38.5
44 Utah 56,298                                164,509                              220,807                              25.5
45 Vermont 23,493                                18,252                                41,744                                56.3
46 Virginia 259,082                              356,337                              615,418                              42.1
47 Washington 317,001                              248,581                              565,582                              56.0
48 West Virginia 50,844                                82,832                                133,676                              38.0
49 Wisconsin 177,210                              177,021                              354,231                              50.0
50 Wyoming 17,652                                22,915                                40,566                                43.5
Total 10,378,465                         15,697,921.13                   26,076,386                         39.8
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6   Measuring for Herd Immunity 
The model developed in this study can be used to measure the impact of herd 
immunity – resistance to the spread of COVID-19 within a population based on pre-
existing immunity from the previous infection for a high proportion of the population. 
Since the dependent variable in the model, casei, is the cumulative COVID-19 
infection case rate in state i from 1/1/21 to 8/10/21, a proxy for pre-existing immunity 
from COVID-19 infection can be defined as: 
 
precasei,t =  ∑ casei,tnt=1        
 
where precasei,t is the cumulative case rate in state i from 1/1/20 to 12/31/20.  Table 9 presents 
the cumulative case rate for precasei,t by state in alphabetical order and rank order from highest 
to lowest as of 12/31/20. 
 
 The functional form of the equation that incorporates the impact of each states pre-
existing immunity as measured by precasei,t is shown below in Equation (7). 
 
casei = bo + b1 vaccinei + b2 densityi +  b3 sdensityi + b4 povertyi + b5 precasei         (7) 
 
where the variables for state i are as defined in Table 2, precasei is as defined above and b0 … b5 
are parameters to be estimated. 
 
Note: Error terms are suppressed. 
 
The hypothesized signs of association in Equation (7) are shown below in Equation (8). 
 
                      +           +              +            +            - 
casei = f  (vaccine; density;  sdensity; poverty; precase)             (8) 
 
The empirical results of testing Equation (7) are presented below in Table 10. 
 
 As in the empirical results of Regression 5, all of the variables except for precasei are 
significant and have the hypothesized signs of association.  The variable serving as a proxy for 
the impact of herd immunity, precasei, has the hypothesized negative sign, but p= 0.21 is just 
short of passing a one-tailed 0.10 significance test. 
 This empirical finding does not necessarily mean there is no herd immunity resulting 
from the COVID-19 pandemic.  More likely,  the mean cumulative case rate of 6,336 per 
100,000 for all states as of 12/31/20 (See Table 9) may not be high enough to lead to a significant 
resistance response during the 1/1/20 to 8/10/21 period. 
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Table 9
Cumulative COVID case rate as of 12/31/20 (precase)
State Alpha Order State Rank Order
1 Alabama 7,340               1 North Dakota 12,086        
2 Alaska 6,430               2 South Dakota 11,108        
3 Arizona 7,010               3 Wisconsin 8,923           
4 Arkansas 7,429               4 Iowa 8,905           
5 California 5,907               5 Nebraska 8,609           
6 Colorado 5,753               6 Tennessee 8,521           
7 Connecticut 5,221               7 Utah 8,511           
8 Delaware 5,822               8 Rhode Island 8,320           
9 Florida 6,089               9 Kansas 7,729           
10 Georgia 6,223               10 Idaho 7,722           
11 Hawaii 1,564               11 Illinois 7,654           
12 Idaho 7,722               12 Wyoming 7,626           
13 Illinois 7,654               13 Indiana 7,572           
14 Indiana 7,572               14 Montana 7,547           
15 Iowa 8,905               15 Arkansas 7,429           
16 Kansas 7,729               16 Minnesota 7,341           
17 Kentucky 5,925               17 Alabama 7,340           
18 Louisiana 6,787               18 Oklahoma 7,315           
19 Maine 1,792               19 Mississippi 7,274           
20 Maryland 4,569               20 Missouri 7,165           
21 Massachusetts 5,442               21 Nevada 7,161           
22 Michigan 5,304               22 Arizona 7,010           
23 Minnesota 7,341               23 Louisiana 6,787           
24 Mississippi 7,274               24 New Mexico 6,783           
25 Missouri 7,165               25 Alaska 6,430           
26 Montana 7,547               26 Georgia 6,223           
27 Nebraska 8,609               27 Florida 6,089           
28 Nevada 7,161               28 Texas 6,038           
29 New Hampshire 3,285               29 Ohio 5,990           
30 New Jersey 5,956               30 New Jersey 5,956           
31 New Mexico 6,783               31 Kentucky 5,925           
32 New York 5,062               32 California 5,907           
33 North Carolina 5,090               33 South Carolina 5,893           
34 North Dakota 12,086             34 Delaware 5,822           
35 Ohio 5,990               35 Colorado 5,753           
36 Oklahoma 7,315               36 Massachusetts 5,442           
37 Oregon 2,686               37 Michigan 5,304           
38 Pennsylvania 5,056               38 Connecticut 5,221           
39 Rhode Island 8,320               39 North Carolina 5,090           
40 South Carolina 5,893               40 New York 5,062           
41 South Dakota 11,108             41 Pennsylvania 5,056           
42 Tennessee 8,521               42 West Virginia 4,781           
43 Texas 6,038               43 Maryland 4,569           
44 Utah 8,511               44 Virginia 4,069           
45 Vermont 1,189               45 New Hampshire 3,285           
46 Virginia 4,069               46 Washington 3,207           
47 Washington 3,207               47 Oregon 2,686           
48 West Virginia 4,781               48 Maine 1,792           
49 Wisconsin 8,923               49 Hawaii 1,564           
50 Wyoming 7,626               50 Vermont 1,189           

































Regression 7 - Regression test of Equation (7) that includes a variable

















Notes:  t statistics in parentheses. *p<0.10, **p<0.05, ***p<0.01 (one-tailed test)
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7   The Impact of Vaccination in reducing the COVID-19 Death Rate 
 
The focus of this study has been on measuring the efficacy of increasing vaccination rates 
on reducing confirmed cases of COVID-19.  It might be argued that in addition to reducing the 
confirmed case rate, vaccinated people have a better chance of surviving after being infected 
with the virus.  That argument can be tested by comparing mortality rates pre- and post-
vaccination periods.  The mortality rate is defined as the ratio of the COVID-19 death rate to the 
COVID-19 case rate. 
Figure 9 shows a comparison of weekly COVID-19 case rates and death rates from 






The timing of that lag can be analyzed by comparing correlation coefficients between 
weekly COVID-19 death rates and various weekly lags of confirmed case rates.  As shown in 
Table 11, the highest correlation coefficient of  0.886 suggests a lag of 3 weeks before changes in 
case rates affect death rates.  This finding is also supported by correlation coefficients that 
measure the lag measured in days rather than weeks.  The highest correlation coefficient of 0.843 
when using a lag of 21 days supports the finding that a lag of 3 weeks before case rates affect 
death rates. 
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 The presence of a lag of three weeks or 21 days before the case rate affects the death rate 
needs to be considered when measuring the COVID-19 mortality rate.  That measure, defined as 
the ratio of the COVID-19 death rate to the case rate lagged three weeks, can be expressed in 
percentage terms as follows: 
                                     mratet = [dratet / cratet-3] * 100 
 
  where  mratet   = Mean COVID-19 mortality rate during week t 
    dratet   = Mean COVID-19 death rate during week t 
            cratet-3 = Mean COVID-19 case rate lagged 3 weeks 
 
A graphical representation of the weekly COVID-19 mortality rate, as measured by mrate 
is shown in Figure 10.  That figure shows that the mortality rate, mrate, hovered within a range 
of 1.2 to 1.6 percent through 4/1/21.  Then after peaking at 1.9 percent on 4/7/21, the mortality 
rate dropped sharply to 0.8 percent by 4/21/21.  Perhaps because of the COVID-19 Delta variant, 
the mortality rate subsequently increased to 2.4 percent by 7/21/21 and thereafter declined 
sharply to 1.6 percent by 8/10/21. 
The mean mortality rate, mrate, from 8/1/20 to 12/31/20, was 1.55 percent versus 1.46 
percent during the 1/1/21 to 8/10/21 period, an interval of time when vaccines became available 
and the vaccination rate steadily increased.  But in spite of the increase in the vaccination rate, 
the decrease in the mean weekly mortality rate from 1.55 to 1.46 was not significant.  The 
measured t statistic for a two-sample hypothesis test, assuming unequal variances was an 
insignificant +0.99 with a one-tailed p = 0.16.  These empirical results suggest that vaccinations 
had no significant impact in reducing the COVID-19 mortality rate, at least when comparing the 
8/1/20 to 12/31/20 period with the 1/1/21 to 8/10/21 period. 
Although no significant impact was found in the mortality rate, it should be noted that 
this study points to a sharp decline in the number of deaths as a result of vaccinations.  Given a 
mortality rate of 1.46 during the 1/1/21 to 8/10/21 period and an estimated total decline of 16.7 
million cases through 8/10/21 (see Figure 5), the total estimated decline in COVID-19 deaths 
from vaccinations is about 245,000 lives or (16.7 million * 0.0146). 
Table 11
Correlation Coefficients (r-values) that Measure the Lag in Weeks and Days
between COVID-19 Case Rates and Death Rates from 3/1/20 to 8/10/21
r-value r-value
Case (-0) 0.803 Case (-18) 0.700
Case (-1) 0.857 Case (-19) 0.766
Case (-2) 0.881 Case (-20) 0.827
Case (-3) 0.886 Case (-21) 0.843
Case (-4) 0.863 Case (-22) 0.779
Weeks Days
















8   Conclusion 
 
 Much controversy has arisen over the efficacy of COVID-19 vaccinations and the efforts 
taken or not taken by state governments to increase their mean vaccination rates.  In spite of this, 
no academic papers have been published that examine statewide differences in COVID-19 
vaccination rates and case rates.  This study hopes to fill that gap by presenting a stepwise 
regression test that measures the hypothesized impact of vaccinations and other explanatory 
variables on each state’s COVID-19 case rate. 
 The empirical findings presented in Table 4 show that the vaccination rate, two measures 
of density, and the poverty rate are all significant at the p < 0.05 (one-tailed) level or higher and 
have the hypothesized signs of association.  The measured t statistic of -3.67 for the state’s 
vaccination rate is highly significant at the p < 0.01 level (one-tailed).  On average, the 
regression findings suggest a state’s COVID-19 case rate changes by -85.94 cases per 100,000 in 
population for every increase of 1 percent in a state’s vaccine rate.  That, in turn, suggests that 
the mean cumulative case rate in the U.S. of 40.1 per 100,000 on 8/10/21 resulted in a decline of 
3,446 cases per 100,000 or (40.1 * -85.94).  That represents a decrease in the total number of 
cases in the U.S. of 11.4 million COVID-19 confirmed cases as a result of the various COVID-
19 vaccines. 
 A “what-if” scenario had the mean vaccination rate been 50 instead of 40.1 points to a 
further decline of 851 cases per 100,000, or a total reduction of 2.8 million confirmed COVID-19 
cases. 
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 The analysis was also extended to compare actual and estimated cumulative COVID-19 
case rates with and without vaccination over the 1/1/21 to 8/10/21 period (see Figure 5).  Based 
on a mean cumulative vaccination rate of 58.9 percent, the findings point to a difference of 5,062 
fewer cases per 100,000 in the U.S.  That is equivalent to a total reduction of 16.7 million cases 
through 8/10/21.  Assuming a COVID-19 death rate of 1.46 percent (see Section 7), that suggests 
that about 245,000 lives have been saved because of vaccines. 
 A constant rate elasticity of -0.70 was estimated in a double logarithmic version of the 
best-fit equation.  That estimate compared closely to the average elasticity of -0.79 in the linear 
version of the best-fit equation. 
 Density was the most significant variable tested over the 1/1/21 to 8/1/21 period.  
Empirical evidence, however, suggests that the impact of density on cumulative COVID-19 
cases changed over time.  While it was highly significant in the first half of 2020, its significance 
evaporated during the second half.  These findings suggest that COVID-19 hit dense states hard 
during the initial stage of the pandemic (1/1/20 to 6/30/20), but that impact fell away during the 
second half.  But density returned as being a highly significant variable from 1/1/21 to 8/10/21. 
 The poverty variable that measured the mean poverty rate in each state was significant 
during all three periods tested in the study.  A constant elasticity of 0.25 for the variable over the 
1/1/21 to 8/10/21 period suggests that a one percent increase in a state’s poverty rate leads to a 
0.25 percent increase in its COVID-19 case rate. 
In analyzing the efficacy of governmental policy mandates, the empirical results shown in 
Table 6 suggest that the stringency variable was significant throughout 2020 and particularly so 
during the 7/1/20 to 12/31/20 period.  In fact, stringency was the only explanatory variable 
during the second half of 2020 that had a p < 0.05 or higher level of significance.  But in 2021, it 
exhibited no significance in reducing statewide case rates.  This finding may have resulted from 
the sharp decline in the use of mandates in 2021. 
Table 8 on page 24 presents the estimated impact on each state’s mean vaccinated rate 
and the actual number of cases, given each state’s mean vaccination rate over the 1/1/20 to 
8/10/21 period. 
 In testing for the presence of herd immunity in 2021, the empirical results had the 
hypothesized sign of association, but its significance (p = 0.21) was short of passing a one-tailed 
0.10 significance test. 
 Finally, the empirical findings of this study point to a 21-day or 3-week lag before 
COVID-19 case rates affect COVID-19 death rates.  The presence of that lag was used to test the 
relationship between cases and deaths over several time periods.  The empirical results suggest 
that unlike the highly significant impact of vaccinations in reducing COVID-19 case rates, they 
had no significant impact in reducing the COVID-19 mortality rates, at least when comparing the 
8/1/20 to 12/31/20 period with the 1/1/21 to 8/10/21 period. 
 Future research should be directed at extending the study through September 2021 in 
order to better measure the impact of the recent surge in COVID-19 cases and deaths from the 
Delta variant on the other variables tested in this study.  The model can also be extended to 
directly examine the impact of the vaccinations and other variables on the COVID-19 death rate 
rather than the indirect test used in the final section of this study. 
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